Underwriter (Number Of IPOs As Lead/Number of IPOs As Lead Or Comanager)

After-Market Performance (Average)**

Deutsche Banc Alex. Brown (1/1)

+96%

A.G. Edwards & Sons Inc. (0/1)

+96%

Donaldson, Lufkin & Jenrette (1/1)

+85%

Warburg Dillon Read LLC (0/2)

+81%

BancBoston Robertson Stephens (0/1)

+77%

Goldman, Sachs & Co. (0/1)

+77%

Merrill Lynch & Co. (0/1)

+77%

China Everbright Securities Ltd. (0/1)

+70%

The New China Hong Kong Securities Ltd. (0/1)

+70%

Westport Resources Investment Services (1/1)

+70%

Prudential Vector Securities (1/2)

+68%

Hambrecht & Quist LLC# (0/1)

+54%

ING Baring Furman Selz LLC (1/1)

+54%

U.S. Bancorp Piper Jaffray (1/2)

+54%

Punk, Ziegel & Co. (0/1)

+40%

J.P. Morgan & Co. (2/2)

+27%

Leerink Swann & Co. (0/1)

+23%

Schroders Securities Ltd. (0/1)

+23%

Vontobel Securities Ltd. (0/1)

+23%

Adams, Harkness & Hill Inc. (0/1)

-23%

Robert W. Baird & Co. (0/1)

-23%

Notes:

These charts are updated from those that appeared Aug. 30 to reflect the addition of United Therapeutics Corp's $62.1 million initial public offering in June. Deutsche Banc Alex. Brown was the lead underwriter. A.G. Edwards & Sons Inc and Prudential Vector Securities were co-managers

*The offerings in this chart include only those that were completed on U.S. stock exchanges (NASDAQ, NYSE, or AMEX), the Canadian Stock Exchange (TSE) and the London Stock Exchange (LSE) from January-July 1999. Gross proceeds exclude additional funding raised from the excercise of overallotment options

**After-market performance is expressed as the percent change in stock price between the IPO price and the closing price on 8/25/99. For underwriters with multiple offerings, the after-market performance (as a percent change) was calculated for each stock in that underwriter's "group", the percentage summed, and then averaged.

# Hambrecht & Quist LLC acted as placement agent for Ribozyme Pharmaceutical Inc.'s 7/99 follow-on offering